pharma · Migraine · Narcolepsy
H. Lundbeck A/S
H. Lundbeck A/S is a pharma organization headquartered in Valby, CN. Primary therapeutic focus areas include Migraine, Narcolepsy, Schizophrenia, Multiple System Atrophy, Chronic Migrane, Migrane, Medication Overuse Head
Postboks 361, LYSAKER, Bærum 1326, NO, Valby, CN HQ
112 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Postboks 361, LYSAKER, Bærum 1326, NO, Valby, CN
- Employees
- 112
- Programs
- 17
- Drugs
- 14
- Patents
- 0
Bifeprunox
Phase 3 · small molecule · Schizophrenia
Bifeprunox for Schizophrenia is a Phase 3 program (small_molecule) at H. Lundbeck A/S with 1 ClinicalTrials.gov record(s).
Internal code 11916A
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- H. Lundbeck A/S
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Schizophrenia
- Status
- terminated
- Trials
- 1